 Adagio Therapeutics Inc NASDAQ: ADGI shares are plunging during the premarket session after issuing an update following external in vitro analyses to evaluate the neutralizing activity of ADG20 against the omicron variant. The in vitro data generated through both authentic and pseudovirus testing of the omicron variant shows a greater than 300-fold reduction in neutralizing activity of ADG20 against omicron. 